By Benjamin Lowentritt, MD  | When a patient learns they have metastatic castration-sensitive prostate cancer (mCSPC), it often marks the beginning of a long and uncertain journey. The first conversat...

By Benjamin Lowentritt, MD  | When a patient learns they have metastatic castration-sensitive prostate cancer (mCSPC), it often marks the beginning of a long and uncertain journey. The first conversat...

The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global...

In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration-sensitive prostate cancer (mCSPC), achieving a prostate-specific antigen (PSA) of <0.2 ng/mL...

The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.

Phase 3 TALAPRO-3 data demonstrate a 52% reduction in the risk of radiographic progression or death with the PARPi/ARPi combination regimen in HRR-altered mCSPC.

The algorithm is broadly aligned with current mCSPC practice for diagnosis, early treatment intensification with AR pathway inhibitors, and routine consideration of germline/somatic testing. However, ...

The algorithm is broadly aligned with current mCSPC practice in emphasizing ADT as backbone therapy, recommending treatment intensification, and incorporating germline/somatic testing to guide therapy...

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

Martin Ignacio Zapata Laguado: ASCO26 Practice-Changing Data in HRR-Mutated mCSPC / ASCO26, BRCA-altered tumors, cancer, Enzalutamide, HRR-mutated mCSPC,

At 3 years, 77% on TALZENNA plus XTANDI were progression-free vs 56% on XTANDI alone in HRR‑mutated mCSPC; Phase 3 TALAPRO‑3 data at ASCO 2026.

Martin W. Schoen, MD, MPH, discusses data from a real-world study of enzalutamide vs apalutamide in mCSPC.

In this study, actigraphy devices were used for more than 12 months to continuously measure sleep quality and physical activity as objective proxies for hot flash burden.

Pfizer (NYSE: PFE) will present new oncology data at ASCO 2026 (May 29–June 2) covering over 40 abstracts, including three late-breaking sessions and eight oral presentations.Key highlights include a 7‑year CROWN update supporting lorlatinib as first-line ALK+ NSCLC, BREAKWATER PFS/OS data for a BRAFTOVI regimen in BRAF V600E mCRC, TALAPRO-3 topline rPFS benefit for TALZENNA + XTANDI in mCSPC, and HER2CLIMB-05 maintenance results for TUKYSA. Multiple next-generation programs (PF‑08634404, sigvotatug vedotin, atirmociclib) advance toward Phase 3 testing.

Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair...

STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見